Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1045 results
April 2020
-
Media ReleaseNovartis Cosentyx® gains fourth indication in EU with first-in-class approval in axial spondyloarthritis spectrumCosentyx® is the first fully-human IL-17A inhibitor indicated for patients in Europe with non-radiographic axial spondyloarthritis (nr-axSpA), which forms part of the axial spondyloarthritis (axSpA)…
-
Key ReleaseNovartis maintains strong operational performance in Q1, confirms FY 2020 guidance at this time, and advances a broad range of efforts to support the global response to COVID-19Q1 2020 net sales from continuing operations1 grew 13% (cc2, +11% USD) with double digit growth (cc) in Innovative Medicines and Sandoz: Key growth drivers include Entresto USD 569…
-
Media ReleaseNovartis announces data showing Jakavi® (ruxolitinib) more effective than best available therapy in acute graft-versus-host diseaseData from Phase III REACH2 study, published in The New England Journal of Medicine, demonstrate Jakavi can improve outcomes for patients with acute graft-versus-host disease (GvHD) who do not respond…
-
Media ReleaseNovartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphomaIf approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults…
-
Media ReleaseAveXis Community Statement on the Coronavirus Disease (COVID-19)Dear SMA Community, Like many organizations across the United States and around the world, AveXis is closely monitoring the coronavirus disease (COVID-19) and its impact on patients, the SMA…
-
Media ReleaseNovartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent® (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed…
-
Media ReleaseNovartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patientsNovartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease Trial…
-
Media ReleaseNovartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye”Technology has potential to reimagine treatment for amblyopia (“lazy eye”), a leading cause of vision loss in children and young adults1Acquisition expands the Novartis refractive disorder pipeline…
-
Media ReleaseNovartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig® as a preventive treatment across the full spectrum of migraineReal-world evidence supports benefits seen in Aimovig clinical trials Open-label data highlight long-term efficacy and safety profile of Aimovig in episodic and chronic migraine Post-hoc…
-
Media ReleaseNovartis announces plan to initiate clinical study of Jakavi® in severe COVID-19 patients and establish international compassionate use programNew clinical trial to evaluate Jakavi® (ruxolitinib) in patients with COVID-19 associated cytokine storm Cytokine storm is a type of severe immune overreaction that can result from coronavirus…
-
Key ReleaseNovartis announces mutual agreement to terminate sale of Sandoz US generic oral solids, dermatology portfolio to AurobindoBasel, April 2, 2020 – Novartis today announced the mutual agreement with Aurobindo Pharma USA Inc. to terminate the agreement to sell the Sandoz US generic oral solids and dermatology businesses to…
Pagination
- ‹ Previous page
- 1
- …
- 30
- 31
- 32
- 33
- 34
- 35
- 36
- …
- 88
- › Next page